摘要
目的:研制用于治疗尿毒症的新型血液灌流吸附剂,通过与已上市血液灌流产品对照研究探讨其对肌酐、尿酸和β2微球蛋白的清除效果及血液相容性。方法:通过体外血浆吸附实验研究血液灌流吸附剂对肌酐、尿酸和β2微球蛋白的清除效率,通过血浆蛋白吸附性、电解质吸附性、血细胞吸附性、溶血性以及凝血性实验评价血液灌流吸附剂的血液相容性。结果:新型HB-H-10血液灌流吸附剂对肌酐、尿酸和β2微球蛋白的吸附率分别达(40.5±2.3)%、(24.2±1.8)%和(46.9±1.3)%,与其他吸附剂相比,吸附效果具有统计学意义(P<0.05);该吸附剂对血浆蛋白总蛋白、白蛋白、球蛋白、白细胞、红细胞和血小板吸附率分别为(5.69±0.32)%、(4.76±0.42)%、(7.33±0.33)%、(2.88±0.32)%、(9.22±0.26)%和(11.98±0.43)%,与其他吸附剂相比,吸附效果具有统计学意义(P<0.05);该吸附剂对血浆电解质、溶血率、凝血影响无统计学意义(均P>0.05),具有优异的血液相容性。结论:研制的新型HB-H-10吸附剂可作为血液灌流吸附剂治疗尿毒症,达到该产品更新换代和升级的效果。
Objective:To develop a new kind of hemoperfusion adsorbent to cure uremia,and study the clearance effect on creatinine,uric acid,β2-microglobulin and hemocompatibility by comparing with the clinical hemoperfusion products.Methods:The clearance efficiency of hemoperfusion adsorbents on creatinine,uric acid andβ2-microglobulin were studied by plasma adsorption experiment in vitro.The hemocompatibilities were evaluated by plasma protein adsorption,electrolyte adsorption,blood cell adsorption,hemolysis rate and coagulation experiment.Results:The clearance efficiency of HB-H-10 hemoperfusion adsorbent on creatinine,uric acid andβ2-microglobulin were(40.5±2.3)%,(24.2±1.8)%and(46.9±1.3)%.The clearance efficiency was statistically significant compared with other adsorbents(P<0.05).The adsorption rates of HB-H-10 hemoperfusion adsorbent on total protein,albumin,globulin,white blood cells,red blood cells and platelets were(5.69±0.32)%,(4.76±0.42)%,(7.33±0.33)%,(2.88±0.32)%,(9.22±0.26)%and(11.98±0.43)%.Compared with the other adsorbents,the adsorption rates of HB-H-10 hemoperfusion adsorbent were statistically significant(P<0.05).The adsorbent had no significant effect on plasma electrolyte,hemolysis rate and coagulation(all P>0.05).It had excellent hemocompatibility.Conclusion:The new HB-H-10 adsorbent is expected to be used as hemoperfusion adsorbent in the treatment of uremia.It can achieve the effect of updating and upgrading the presented products.
作者
李可
刘娟娟
刘辉
舒桂明
袁玉华
LI Ke;LIU Juan-juan;LIU Hui;SHU Gui-ming;YUAN Yu-hua(School of Laboratory Medicine,Tianjin Medical University,Tianjin 300070,China;Department of Laboratory,Tianjin Children's Hospital,Tianjin 300074,China;Artificial Cell Engineering Technology Research Center of Public Health Ministry,Department of Institute of Hepatobiliary Disease,Tianjin Third Central Hospital,Tianjin 300170,China;Tianjin Key Laboratory of Hemoperfusion Technology,Tianjin 300170,China;Department of Laboratory,Airport Hospital,General Hospital,Tianjin Medical University,Tianjin 300308,China)
出处
《天津医科大学学报》
2021年第3期291-295,306,共6页
Journal of Tianjin Medical University
基金
天津市科技支撑项目(20YFZCSY00310)
天津市重点实验室项目(16PTSYJC00210)。
